$CPRX
CATALYST PHARMACEUTICALS, INC.

2014 Q1 Form 10-K Financial Statement

#000119312514104658 Filed on March 19, 2014

View on sec.gov

Income Statement

Concept 2014 Q1 2013 2012 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $760.0K $2.200M $760.0K
YoY Change 24.59% -15.38% -28.97%
% of Gross Profit
Research & Development $2.749M $8.097M $740.0K
YoY Change 151.64% 204.44% -22.92%
% of Gross Profit
Depreciation & Amortization $5.285K $22.48K $0.00
YoY Change -1.47% 106.47% -100.0%
% of Gross Profit
Operating Expenses $3.508M $10.31M $1.510M
YoY Change 105.72% 97.5% -25.62%
Operating Profit -$3.508M -$10.31M -$1.505M
YoY Change 105.72% 97.5%
Interest Expense -$340.0K -$1.900M $1.420M
YoY Change 580.0% -272.73% -543.75%
% of Operating Profit
Other Income/Expense, Net $32.76K $47.42K $10.00K
YoY Change 227.6% 216.65%
Pretax Income -$3.811M -$12.15M -$80.00K
YoY Change 118.49% 198.17% -96.6%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.811M -$12.15M -$76.59K
YoY Change 118.49% 198.17% -96.74%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$70.37K -$268.1K -$2.195K
COMMON SHARES
Basic Shares Outstanding 54.15M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q1 2013 2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.30M $23.70M $15.40M
YoY Change 61.36% 53.9% 156.67%
Cash & Equivalents $1.072M $2.200M $1.410M
Short-Term Investments $20.20M $21.50M $14.00M
Other Short-Term Assets $900.0K $1.600M $1.300M
YoY Change -25.0% 23.08% 550.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $22.17M $25.30M $16.73M
YoY Change 53.94% 51.5% 169.79%
LONG-TERM ASSETS
Property, Plant & Equipment $52.65K $0.00 $53.68K
YoY Change -47.35% -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $0.00
YoY Change
Total Long-Term Assets $61.54K $100.0K $62.57K
YoY Change -38.46% 0.0%
TOTAL ASSETS
Total Short-Term Assets $22.17M $25.30M $16.73M
Total Long-Term Assets $61.54K $100.0K $62.57K
Total Assets $22.23M $25.40M $16.79M
YoY Change 53.31% 51.19% 170.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $932.1K $900.0K $1.366M
YoY Change 55.35% -35.71% 355.22%
Accrued Expenses $1.505M $1.300M $281.0K
YoY Change 276.16% 333.33% -53.17%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.437M $2.100M $1.647M
YoY Change 143.67% 31.25% 105.83%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.200M $1.800M $498.6K
YoY Change 266.67% 260.0% -70.67%
Total Long-Term Liabilities $2.200M $1.800M $498.6K
YoY Change 266.67% 260.0% -70.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.437M $2.100M $1.647M
Total Long-Term Liabilities $2.200M $1.800M $498.6K
Total Liabilities $4.591M $4.000M $2.167M
YoY Change 206.09% 81.82% -13.31%
SHAREHOLDERS EQUITY
Retained Earnings -$58.14M -$42.18M
YoY Change
Common Stock $54.15K $41.42K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $17.64M $21.40M $14.62M
YoY Change
Total Liabilities & Shareholders Equity $22.23M $25.40M $16.79M
YoY Change 53.31% 51.19% 170.79%

Cashflow Statement

Concept 2014 Q1 2013 2012 Q4
OPERATING ACTIVITIES
Net Income -$3.811M -$12.15M -$76.59K
YoY Change 118.49% 198.17% -96.74%
Depreciation, Depletion And Amortization $5.285K $22.48K $0.00
YoY Change -1.47% 106.47% -100.0%
Cash From Operating Activities -$2.430M -$9.876M -$1.590M
YoY Change 8.0% 92.12% 10.42%
INVESTING ACTIVITIES
Capital Expenditures $17.31K $9.432K -$40.00K
YoY Change 83.46% -81.99%
Acquisitions
YoY Change
Other Investing Activities $1.280M -$7.490M -$14.01M
YoY Change -14.09% -46.54%
Cash From Investing Activities $1.270M -$7.497M -$14.05M
YoY Change -14.77% -46.68% -799.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 20.00K 18.18M 5.080M
YoY Change 24.67% 53.47%
NET CHANGE
Cash From Operating Activities -2.430M -9.876M -1.590M
Cash From Investing Activities 1.270M -7.497M -14.05M
Cash From Financing Activities 20.00K 18.18M 5.080M
Net Change In Cash -1.140M 806.0K -10.56M
YoY Change 50.0% -117.45% -372.16%
FREE CASH FLOW
Cash From Operating Activities -$2.430M -$9.876M -$1.590M
Capital Expenditures $17.31K $9.432K -$40.00K
Free Cash Flow -$2.447M -$9.885M -$1.550M
YoY Change 8.32% 90.36% 7.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
54145633 shares
CY2013Q2 dei Entity Public Float
EntityPublicFloat
32240770
CY2002Q1 us-gaap Stockholders Equity
StockholdersEquity
100000
CY2002Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100000
CY2002Q4 us-gaap Stockholders Equity
StockholdersEquity
44888
CY2003Q4 us-gaap Stockholders Equity
StockholdersEquity
362563
CY2004Q4 us-gaap Stockholders Equity
StockholdersEquity
117576
CY2005Q4 us-gaap Stockholders Equity
StockholdersEquity
446462
CY2006Q4 us-gaap Stockholders Equity
StockholdersEquity
19846633
CY2007Q4 us-gaap Stockholders Equity
StockholdersEquity
16322757
CY2008Q4 us-gaap Stockholders Equity
StockholdersEquity
10560215
CY2009Q4 us-gaap Stockholders Equity
StockholdersEquity
7617860
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
5517779
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5475158
CY2011Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1645240
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
3760698
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6029067
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41420687 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41420687 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.89
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3650535 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
281002
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
69963
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
10666
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
56759697
CY2012Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
302880
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1365663
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
51050
CY2012Q4 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
21878
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1646665
CY2012Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
498587
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
14622115
CY2012Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
5949
CY2012Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
498587
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-42179003
CY2012Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
22643
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
41421
CY2012Q4 cprx Accrued Non Clinical And Clinical Trial Expenses
AccruedNonClinicalAndClinicalTrialExpenses
197572
CY2012Q4 cprx Net Operating Loss Carryforward And Start Up Costs
NetOperatingLossCarryforwardAndStartUpCosts
13956000
CY2012Q4 cprx Prepaid Subscription Fees
PrepaidSubscriptionFees
12369
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54132937 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3088905 shares
CY2013Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
3428906 shares
CY2012Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
765
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16789245
CY2012Q4 us-gaap Liabilities
Liabilities
2167130
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Accrued Rent Noncurrent
AccruedRentNoncurrent
21878
CY2012Q4 us-gaap Prepaid Insurance
PrepaidInsurance
143520
CY2012Q4 us-gaap Assets Current
AssetsCurrent
16726678
CY2012Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
8888
CY2012Q4 us-gaap Assets
Assets
16789245
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1409939
CY2012Q4 us-gaap Short Term Investments
ShortTermInvestments
7504444
CY2012Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
14713
CY2012Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
15591000
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
123642
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1309470
CY2012Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
6502825
CY2012Q4 us-gaap Prepaid Rent
PrepaidRent
683
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
53679
CY2012Q4 cprx Accrued License Fees Current
AccruedLicenseFeesCurrent
15000
CY2012Q4 cprx Prepaid Research Fee
PrepaidResearchFee
1138185
CY2012Q4 cprx Certificates Of Deposit Fair Value Disclosure
CertificatesOfDepositFairValueDisclosure
6502825
CY2012Q4 cprx Short Term Investments Fair Value Disclosures
ShortTermInvestmentsFairValueDisclosures
7504444
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54132937 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.80
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3428906 shares
CY2013Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
0.83
CY2013Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
0.80
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.83
CY2013Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
3088905 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1288820
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
70576
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
92446
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5546
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
75670718
CY2013Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1307951
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
279616
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
850789
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
117240
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
19131
CY2013Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
0
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
67828
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2139609
CY2013Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1819562
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
21391252
CY2013Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
14539
CY2013Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1819562
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54333599
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
21877
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
54133
CY2013Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
2746
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25369554
CY2013Q4 us-gaap Liabilities
Liabilities
3978302
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
72678
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
68534
CY2013Q4 us-gaap Accrued Rent Noncurrent
AccruedRentNoncurrent
19131
CY2013Q4 us-gaap Prepaid Insurance
PrepaidInsurance
219651
CY2013Q4 us-gaap Assets Current
AssetsCurrent
25320038
CY2013Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
8888
CY2013Q4 us-gaap Assets
Assets
25369554
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
3999388
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2215958
CY2013Q4 us-gaap Short Term Investments
ShortTermInvestments
17483062
CY2013Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
23151
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
19387000
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
133074
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3511386
CY2013Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
30675000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1609442
CY2013Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
4011576
CY2013Q4 us-gaap Prepaid Rent
PrepaidRent
7848
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
40628
CY2013Q4 cprx Accrued License Fees Current
AccruedLicenseFeesCurrent
65000
CY2013Q4 cprx Prepaid Research Fee
PrepaidResearchFee
1334149
CY2003 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
75833
CY2003 cprx Issuance Of Preferred Stock
IssuanceOfPreferredStock
670457
CY2005 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1087750
CY2005 us-gaap Net Income Loss
NetIncomeLoss
-1805380
CY2005 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1046516
CY2006 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1266465
CY2006 us-gaap Net Income Loss
NetIncomeLoss
-2729454
CY2006 cprx Issuance Of Common Stock Initial Public Offering Net
IssuanceOfCommonStockInitialPublicOfferingNet
17638020
CY2006 cprx Issuance Of Preferred Stock Series B Net
IssuanceOfPreferredStockSeriesBNet
3225140
CY2007 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
579687
CY2013Q4 cprx Certificates Of Deposit Fair Value Disclosure
CertificatesOfDepositFairValueDisclosure
4011576
CY2013Q4 cprx Short Term Investments Fair Value Disclosures
ShortTermInvestmentsFairValueDisclosures
17483062
CY2013Q4 cprx Annual Base Salary Next Year
AnnualBaseSalaryNextYear
425000
CY2013Q4 cprx Accrued Non Clinical And Clinical Trial Expenses
AccruedNonClinicalAndClinicalTrialExpenses
1083749
CY2013Q4 cprx Money Market Funds Fair Value
MoneyMarketFundsFairValue
25693
CY2013Q4 cprx Net Operating Loss Carryforward And Start Up Costs
NetOperatingLossCarryforwardAndStartUpCosts
17685000
CY2013Q4 cprx Prepaid Subscription Fees
PrepaidSubscriptionFees
24643
CY2011Q3 cprx Class Of Warrant Or Right Expirations Date
ClassOfWarrantOrRightExpirationsDate
2016-09-20
CY2011Q2 cprx Extension Of Original Lease Term Period
ExtensionOfOriginalLeaseTermPeriod
P5Y
CY2013Q4 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
3 Lawsuits
CY2013Q4 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
3 Lawsuits
CY2002 us-gaap Net Income Loss
NetIncomeLoss
-255945
CY2002 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
75833
CY2002 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
125000
CY2003 us-gaap Net Income Loss
NetIncomeLoss
-428615
CY2007 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
35930
CY2007 us-gaap Net Income Loss
NetIncomeLoss
-4139493
CY2009 us-gaap Net Income Loss
NetIncomeLoss
-7241928
CY2009 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
20152
CY2009 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
581286
CY2009 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3698135
CY2010 us-gaap Net Income Loss
NetIncomeLoss
-4006323
CY2010 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
450089
CY2010 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1456153
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.30 pure
CY2011 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21728292 shares
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.79
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4985049
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2011 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0.47
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0029 pure
CY2011 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5246478 shares
CY2011 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
6
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0155 pure
CY2011 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
31272
CY2011 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
438139
CY2011 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-134025
CY2011 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
1325332
CY2011 us-gaap Investment Income Interest
InvestmentIncomeInterest
10985
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-6082139
CY2011 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2012000
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-6391062
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-6391062
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
416735
CY2011 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
319908
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3620
CY2011 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
93000
CY2011 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
365781
CY2011 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
319908
CY2011 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2698174
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5542578
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
416735
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
553909
CY2011 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
34000
CY2011 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
158001
CY2011 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3620
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3383965
CY2011 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
42835
CY2011 us-gaap Depreciation
Depreciation
42835
CY2011 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
61653
CY2011 us-gaap Operating Expenses
OperatingExpenses
6082139
CY2011 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2011 cprx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
pure
CY2011 cprx Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
5542578
CY2011 cprx Issuance Of Common Stock And Warrants Net
IssuanceOfCommonStockAndWarrantsNet
4217246
CY2013 dei Entity Registrant Name
EntityRegistrantName
CATALYST PHARMACEUTICAL PARTNERS, INC.
CY2013 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2013 dei Amendment Flag
AmendmentFlag
false
CY2013 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2013 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013 dei Document Type
DocumentType
10-K
CY2013 dei Document Period End Date
DocumentPeriodEndDate
2013-12-31
CY2013 dei Entity Central Index Key
EntityCentralIndexKey
0001369568
CY2013 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2013 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2013 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P2Y3M4D
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
3.04
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
116296 shares
CY2013 us-gaap Loss Contingency Claims Dismissed Number
LossContingencyClaimsDismissedNumber
2 Lawsuits
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.37 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35 pure
CY2013 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P2Y22D
CY2013 us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>1.</b></td> <td valign="top" align="left"><b>Organization and Description of Business</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Catalyst Pharmaceutical Partners, Inc. (the &#x201C;Company&#x201D;) is a development-stage specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neurological diseases and disorders, including Lambert-Eaton Myasthenic Syndrome (LEMS) and infantile spasms. The Company was incorporated in Delaware in July 2006. It is the successor by merger to Catalyst Pharmaceutical Partners, Inc., a Florida corporation, which commenced operations in January 2002.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company has incurred operating losses in each period from inception through December&#xA0;31, 2013. The Company has been able to fund its cash needs to date through public and private offerings of its common stock and warrants and through government grants. See Note 11.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i>Capital Resources</i></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> On January&#xA0;31, 2014, the Company filed a shelf Registration Statement on Form S-3 (the 2014 Shelf Registration Statement) with the SEC to sell up to $100 million of common stock. The 2014 shelf Registration Statement has not yet been declared effective. See Note 15.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> While there can be no assurance, based on available information, the Company currently believes that it has sufficient resources to support its planned operations through at least the end of 2014. The Company will require additional capital to support its planned operations in periods after the end of 2014.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company may raise in the future required funds through public or private equity offerings, debt financings, corporate collaborations, governmental research grants or other means. The Company may also seek to raise new capital to fund additional product development efforts, even if it has sufficient funds for its planned operations. Any sale by the Company of additional equity or convertible debt securities could result in dilution to the Company&#x2019;s current stockholders. There can be no assurance that any required additional funding will be available to the Company at all or available on terms acceptable to the Company. Further, to the extent that the Company raises funds through collaborative arrangements, it may be necessary to relinquish some rights to the Company&#x2019;s technologies or grant sublicenses on terms that are not favorable to the Company. If the Company is not able to secure additional funding when needed, the Company may have to delay, reduce the scope of, or eliminate one or more research and development programs, which could have an adverse effect on the Company&#x2019;s business.</p> </div>
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y3M4D
CY2013 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <table> <tr> <td valign="top" width="4%" align="left"><b>s.</b></td> <td valign="top" align="left"><b>RECLASSIFICATIONS.</b> Certain prior year amounts in the financial statements have been reclassified to conform to the current year presentation.</td> </tr> </table> </div>
CY2013 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.15 pure
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45452447 shares
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.60
CY2013 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.04 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.48
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9875674
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.47
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
115000 shares
CY2013 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 Segment
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
170333 shares
CY2013 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0.47
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P2Y22D
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0045 pure
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
50000 shares
CY2013 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <table> <tr> <td valign="top" width="4%" align="left"><b>n.</b></td> <td valign="top" align="left"><b>CONCENTRATION OF CREDIT RISK.</b> The financial instruments that potentially subject the Company to concentration of credit risk are cash equivalents (i.e. money market funds), short-term investments and certificates of deposit. The Company places its cash equivalents with high-credit quality financial institutions. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in these accounts.</td> </tr> </table> </div>
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
1.20
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8277526 shares
CY2013 us-gaap Use Of Estimates
UseOfEstimates
<div> <table> <tr> <td valign="top" width="4%" align="left"><b>b.</b></td> <td valign="top" align="left"><b>USE OF ESTIMATES.</b> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</td> </tr> </table> </div>
CY2013 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
6
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0053 pure
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
299972
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
166633
CY2013 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
9978618
CY2013 us-gaap Investment Income Interest
InvestmentIncomeInterest
47421
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-10311658
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3796000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-12154596
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-12154596
CY2013 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
4652684
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
175855
CY2013 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
1890359
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14095194
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9432
CY2013 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
10000
CY2013 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1005071
CY2013 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1890359
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2214884
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18178494
CY2013 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
569384
CY2013 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4083300
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
17975
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
175855
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
806019
CY2013 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
30000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-514874
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7496801
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8096774
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
23500
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
22483
CY2013 us-gaap Depreciation
Depreciation
22483
CY2013 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
569384
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
69930
CY2013 us-gaap Operating Expenses
OperatingExpenses
10311658
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2013 cprx Minimum Amortization Period Of Compensation Cost On Straight Line Basis
MinimumAmortizationPeriodOfCompensationCostOnStraightLineBasis
P3Y
CY2013 cprx Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1.00 pure
CY2013 cprx Operating Lease Expiration Dates
OperatingLeaseExpirationDates
2017-11
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.32
CY2013 cprx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
pure
CY2013 cprx Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
14071694
CY2013 cprx Maximum Maturity Period Of Cash And Cash Equivalent
MaximumMaturityPeriodOfCashAndCashEquivalent
3 months
CY2013 cprx Maximum Amortization Period Of Compensation Cost On Straight Line Basis
MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis
P5Y
CY2013 cprx Expiration Date Of Employment Agreement With Ceo
ExpirationDateOfEmploymentAgreementWithCeo
2016-11
CY2012 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
5000000
CY2012 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
16249
CY2013 cprx Operating Losses Carryforwards Expiration Dates
OperatingLossesCarryforwardsExpirationDates
Beginning in 2024 and ending in 2033
CY2013 cprx Payments For Proceeds From Certificates Of Deposit
PaymentsForProceedsFromCertificatesOfDeposit
-2491249
CY2004 us-gaap Net Income Loss
NetIncomeLoss
-539820
CY2004 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
294833
CY2008 us-gaap Net Income Loss
NetIncomeLoss
-10564597
CY2008 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
130319
CY2008 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
583836
CY2008 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4087900
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.20 pure
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30033108 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5140366
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2012 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0.47
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0028 pure
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12361405 shares
CY2012 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
6
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0066 pure
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1110354
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
348815
CY2012 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
7504444
CY2012 us-gaap Investment Income Interest
InvestmentIncomeInterest
14976
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-5221140
CY2012 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2151000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4076386
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-4076386
CY2012 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
5000000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
340039
CY2012 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-1129778
CY2012 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
33124
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
52382
CY2012 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
42000
CY2012 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-276505
CY2012 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1129778
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2561543
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14580889
CY2012 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
16875
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
45050
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
340039
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4619128
CY2012 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
28000
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1101729
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14059651
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2659597
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
10889
CY2012 us-gaap Depreciation
Depreciation
10889
CY2012 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
16875
CY2012 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
65310
CY2012 us-gaap Operating Expenses
OperatingExpenses
5221140
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2012 cprx Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1.00 pure
CY2012 cprx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
pure
CY2012 cprx Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
9564640
CY2012 cprx Issuance Of Common Stock And Warrants Net
IssuanceOfCommonStockAndWarrantsNet
9564640
CY2012 cprx Payments For Proceeds From Certificates Of Deposit
PaymentsForProceedsFromCertificatesOfDeposit
6502825
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46450636
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1618330
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
17483062
us-gaap Investment Income Interest
InvestmentIncomeInterest
1540186
us-gaap Revenue From Grants
RevenueFromGrants
488958
us-gaap Operating Income Loss
OperatingIncomeLoss
-54793296
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
3410
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-54333599
us-gaap Net Income Loss
NetIncomeLoss
-54333599
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
5000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
164640
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
3895597
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1244599
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1080489
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18882175
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
70225872
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
586259
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
5000000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4099549
us-gaap Share Based Compensation
ShareBasedCompensation
6138055
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2115958
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
850789
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21659278
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36400079
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
23500
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
187361
us-gaap Operating Expenses
OperatingExpenses
55282254
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
cprx Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
57210636
cprx Non Cash Incentive Received From Lessor
NonCashIncentiveReceivedFromLessor
52320
cprx Payments For Proceeds From Certificates Of Deposit
PaymentsForProceedsFromCertificatesOfDeposit
4011576
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2013Q1 us-gaap Revenue From Grants
RevenueFromGrants
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1705430
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-1744289
CY2013Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-45326
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2012Q1 us-gaap Revenue From Grants
RevenueFromGrants
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1364710
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-1089186
CY2012Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
274207
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2012Q2 us-gaap Revenue From Grants
RevenueFromGrants
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1067364
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-289080
CY2012Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
776919
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2013Q2 us-gaap Revenue From Grants
RevenueFromGrants
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2653529
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-3143590
CY2013Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-498587
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2012Q3 us-gaap Revenue From Grants
RevenueFromGrants
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1283713
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-2621535
CY2012Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1340566
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2013Q3 us-gaap Revenue From Grants
RevenueFromGrants
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3245776
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-5912059
CY2013Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2676601
CY2012Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2012Q4 us-gaap Revenue From Grants
RevenueFromGrants
CY2012Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-1505353
CY2012Q4 us-gaap Net Income Loss
NetIncomeLoss
-76585
CY2012Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1419218
CY2013Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2013Q4 us-gaap Revenue From Grants
RevenueFromGrants
CY2013Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-2706923
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-1354658
CY2013Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1330155

Files In Submission

Name View Source Status
0001193125-14-104658-index-headers.html Edgar Link pending
0001193125-14-104658-index.html Edgar Link pending
0001193125-14-104658.txt Edgar Link pending
0001193125-14-104658-xbrl.zip Edgar Link pending
cprx-20131231.xml Edgar Link completed
cprx-20131231.xsd Edgar Link pending
cprx-20131231_cal.xml Edgar Link unprocessable
cprx-20131231_def.xml Edgar Link unprocessable
cprx-20131231_lab.xml Edgar Link unprocessable
cprx-20131231_pre.xml Edgar Link unprocessable
d660168d10k.htm Edgar Link pending
d660168dex231.htm Edgar Link pending
d660168dex311.htm Edgar Link pending
d660168dex312.htm Edgar Link pending
d660168dex321.htm Edgar Link pending
d660168dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g660168g17h74.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending